IPP Bureau
EMA grants GMP Certificate of compliance to CuraTeQ biosimilars’ Hyderabad facility
By IPP Bureau - November 13, 2024
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Divyesh Maru appointed CFO of Hester Biosciences
By IPP Bureau - November 13, 2024
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
Hikal Q2 FY25 revenue stood at Rs. 453 Cr
By IPP Bureau - November 13, 2024
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Tata Chemicals Europe to invest Rs. 655 crore on expansion of pharmaceutical grade sodium bicarbonate capacity
By IPP Bureau - November 13, 2024
Construction of the plant will commence in 2025 with first production expected to be in 2027
Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr
By IPP Bureau - November 11, 2024
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Zydus Wellness Q2 FY25 sales up 12% at Rs. 490.7 Cr
By IPP Bureau - November 11, 2024
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules
By IPP Bureau - November 11, 2024
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr
By IPP Bureau - November 11, 2024
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Pfizer INDovation program boosts six start-ups with Rs. 1.5 crore grant
By IPP Bureau - November 11, 2024
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
USFDA classifies Biocon Biologics’ Biocon Park in Bengaluru as VAI
By IPP Bureau - November 11, 2024
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
Granules India’s Unit V facility secures USFDA EIR with NAI status
By IPP Bureau - November 10, 2024
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr
By IPP Bureau - November 10, 2024
Q2 FY25 Total Income was at Rs. 85.4 crore
Fortis Healthcare Q2 FY25 PAT up 5% at Rs. 193 Cr
By IPP Bureau - November 10, 2024
Hospital business revenues increase 13.9% to Rs. 1,655 crore
